Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer View more
Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309 View more